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ReviewBackground: Intralymphatic metastases (ILM) originate from tumor cell emboli entrapped in dermal lym-
phatics between primary tumor and regional lymph node basin. Because of this origin, sentinel lymph
node biopsy (SLNB) might increase ILM by restricting lymph flow.
Methods: Pubmed, Embase, Cochrane and Medline were searched for articles on ILM between 1980 and
September 2014. ILM Incidences were calculated after wide local excision (WLE), excision with elective
lymph node dissection (ELND) or therapeutic lymph node dissection (TLND), WLE with SLNB with or
without completion lymph node dissection (CLND) and delayed lymph node dissection (DLND) for
patients developing nodal metastasis during follow-up.
Results: In 36 studies, 14,729 patients underwent WLE, 1682 patients WLE/ELND, 362 patients WLE/
DLND and 11,201 patients WLE/SLNB. On meta-analysis, ILM occurrence was 3.4% (95% CI 2.8–4.2%).
ILM occurred most frequently in the WLE/DLND group (5.5%, 95% CI 3.5–8.7%), followed by WLE/ELND
(4.7%, 95% CI 3.1–7.0%), WLE/SLNB (4.5%, 95% CI 3.5–5.7%) and WLE alone (1.9%, 95% CI 1.4–2.7%).
1330 SLNB+ patients were identified and 5783 SLNB patients. For these groups, on meta-analysis,
ILM recurrence was 13.2% (95% CI 10.8–16.2%) and 3.4% (95% CI 2.5–4.5%), respectively (p = 0.01).
Conclusion: In this review SLNB is associated with an increase of ILM with an incidence of 1.9% for WLE
vs. 3.4% for SNLB. Selection bias in this review cannot be excluded. However, ILM occur four times more
frequently after SLNB+ than SLNB procedures and more often after SLNB+/CLND than WLE/DLND or
WLE/ELND. ILM should therefore be viewed as a bio-marker of aggressive primary disease.
Synopsis: Sentinel lymph node biopsy is thought to increase intralymphatic metastasis by restricting
lymph flow. This review demonstrates that there is an increase in metastasis, but this result has to be
interpreted with caution due to possible selection bias. Aggressive tumor characteristics are likely the
cause of this increase.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
The behavior of cutaneous melanoma is notoriously unpre-
dictable. 5-year survival rates deteriorate as stage progresses. For
stage IA, IB, IIA, IIB, and IIC these survival rates are 97%, 92%,
81%, 70% and 53%, respectively. 5-year survival for locoregional
metastasis is 78% (stage IIIA), 59% (stage IIIB) and 40% (stage IIIC)
[1]. Once melanoma has metastasized distantly survival is around
15–20%, although these rates are expected to improve upon therecent introduction of BRAF targeted drugs, checkpoint inhibitors
and new generation immunotherapies [2–9]. Long-term follow-
up reveals that ulceration and sentinel lymph node status are the
strongest predictors for survival [10,11].
The concept of incidence of locoregional metastases increasing
with tumor thickness was recognized decades ago [12–14]. Previ-
ously, in transit metastases (ITM) and satellite lesions (SL) were
considered different entities, but The American Joint Committee
on Cancer (AJCC) has classified both ITM and SL in 2002 as intra-
lymphatic metastases (ILM) [15]. Historically, SL have been defined
to reside within centimeters of the primary tumor location and
ITM in the pathway between primary site and regional lymph node
basin. The leading hypothesis is that both originate from tumor cell
emboli entrapped in dermal lymphatic vessels between primary
tumor and regional lymph node basin [16,17]. The appearance of
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decreasing 5-year survival to 59% and 40%, respectively [1]. Sur-
vival rates for patients with SL alone, SL/ITM, or ITM are identical
and similar to that of patients with nodal disease [18]. Scar recur-
rence, ‘true local recurrence’, differs in pathophysiology, as these
develop from residual cells of the initial melanoma, a result of
false-negative margins or microsatellites.
Curative treatment for primary melanoma remains surgery
(wide local excision, WLE) [2,19]. Four prospective additional elec-
tive lymph node dissection (ELND) trials showed no impact on sur-
vival [20–24]. ELND has become redundant after the introduction
of the sentinel lymph node biopsy (SLNB) in 1992, which preserves
its diagnostic advantage with less morbidity [21–23,25–27].
Patients with a positive SLNB undergo a completion node dissec-
tion (CLND). The MSLT-I study showed a small but significant
disease-free and melanoma-specific survival benefit in patients
with intermediate thickness melanoma (1.2–3.5 mm) and nodal
disease following early treatment [28]. Most notably, a
melanoma-specific survival improvement of 20% was reported
for patients with intermediate thickness melanoma undergoing
SLNB as opposed to observation, although the MSLT-I did not show
improvement in recurrence free, distant metastasis free and mela-
noma specific survival for the entire population. The MSLT-II study
will answer in the near future whether a CLND is indeed indicated
after a positive SLNB [29,30]. Other treatment modalities have
included therapeutic lymph node dissection (TLND), for metastatic
nodal disease at the time of diagnosis, and delayed lymph node
dissection (DLND), for patients developing metastatic nodal dis-
ease [31].
SLNB in addition to WLE alone has been suspected of causing
ILM by inducing lymphatic stasis or entrapment of melanoma cells
[32,33]. Pathophysiology on which this hypothesis is built is that
the lymph flow from the skin reaches the nodal basin within min-
utes, with melanoma cells still in lymphatic channels en route to
the lymph node basin at the time of SLNB or nodal dissection
[33,34]. Estourgie et al. published a fourfold risk of ITM recurrence
in SLNB positive patients as compared to SLNB negative patients,
thereby raising the question whether surgical treatment of the
regional lymph node basin can be responsible for ITM, although
the same research group refuted this finding in a larger population
[35,36]. Although various authors have studied this phenomenon,
most notably Morton et al. in the aforementioned MSLT-I trial
and van Poll et al. using data of the Melanoma Institute Australia,
a definite answer as to whether the incidence of ILM should be
attributed to unfavorable primary tumor characteristics alone or
is increased by the SLNB procedure by means of a review of all
available data has not yet been published [10,16,28,37,38].
The objective of this review was to provide an extensive body of
evidence, answering the question whether ILM frequencies
increase after performing SLNB.Methods
Pubmed, Embase, Cochrane Library and Medline were searched
for articles using the terms ‘melanoma’ and ‘recurrence’ or ‘in tran-
sit metastasis’ or ‘ITM’ or ‘SL’ or ‘intralymphatic metastasis’ or ‘lo-
cal recurrence’ or ‘satellite’ or ‘sentinel node’ or ‘survival’ between
January 1980 and September 2014. Articles were excluded if they
had not been written in English, if they did not distinguish
between a local recurrence and ILM, if incidence for ILM as a first
recurrence (FR) was not reported, if studies exclusively reported
on SLNB or SLNB+ or if treatment strategy was unclear. Dupli-
cates, case reports, letters to the editors and case series were
excluded. Data regarding ILM as FR derived from our institution’s
SLNB database (UMCG database) were added to the review.ITM was classified as recurrent melanoma in the pathway
between primary melanoma location and the regional nodal basin,
with the lesion more than two or five centimeters from this loca-
tion, depending on the definition used in the article. All other cuta-
neous and subcutaneous metastases between the re-excision scar
and the location of ITM were classified as SL. As consensus is
now that ITM and SL are the same entity, all ITM and SL were com-
bined into one value, ‘ILM’.
For all included articles the number of patients with ILM as first
recurrence (FR) were calculated per treatment group: for WLE
alone, for WLE with ELND, WLE and DLND or TLND and WLE with
SLNB. The last group was stratified into tumor-negative SLNB
(SLNB) patients and tumor-positive SLNB (SLNB+) patients
undergoing CLND. When assessing risk of ILM as FR, WLE was com-
pared to the WLE/SLNB group. WLE/SLNB+ was compared to
WLE/DLND, WLE/ELND and WLE/TLND groups. As only SLNB+
patients undergo additional CLND, this division groups together
the most similar procedures regarding interruption of lymph flow.
Additional study characteristics were collected: study design,
number of patients, mean/median Breslow thickness, age at diag-
nosis, and melanoma ulceration status.Statistical analysis
For a comprehensive review of the data, all data were summa-
rized in tables and analyzed using version 18 SPSS, (IBM, Chicago,
Illinois, USA). Descriptive statistics were used to calculate frequen-
cies of ILM for the different treatment strategies. Chi-square tests
were used to check for significant differences.
Subsequently, all studies were assigned a weight based on the
amount of included patients and entered into a meta-analysis.
Meta-analyses were performed stratified for treatment, SLNB
results and anatomical localization of the primary tumor. Propor-
tions of ILM and the corresponding 95% CI were calculated and
entered in a datasheet. Meta-analyses were performed with the
‘metan’ module using STATA/SE version 12.0 (StataCorp, College
Station, Texas, USA) with the original data as reported in the stud-
ies. Pooled ILM proportions and their 95% CI were calculated using
a random effects model.Results
Study characteristics
19,620 studies were identified and assessed according to the
inclusion criteria. 36 studies with a total of 33,622 patients were
included for analysis (Table 1), including our ongoing academic
medical center database (UMCG database). 6 studies were
excluded because they exclusively reported on SLNB or exclu-
sively on SLNB+ patients (n = 684 patients) [11,39–43]. Median
follow-up ranged from >12 months–11 years. Fifteen out of 36
studies reported mean Breslow depth and 6 reported exclusively
median Breslow depth. One study reported Breslow depth using
incremental depths [44]. Melanoma ulceration status was reported
in 23 studies; in 15 of those data were only available for part of the
population. Twelve studies provided treatment/recurrence data on
WLE (14,729 patients), 5 on WLE/ELND (1682 patients), 1 on WLE/
DLND (362 patients) and 18 on WLE/SLNB (11,201 patients). For
the remaining 5648 patients in 7 studies, treatment was not spec-
ified. No study reported outcomes exclusively for TLND.
In 23 of the 36 included studies a clear definition of ITM/SL was
not provided. ITM was defined as (sub)cutaneous disease recur-
rence between locoregional lymph node basin and 2, 3 or 5 cen-
timeters from the original scar in n = 5, n = 1 and n = 4 studies,
respectively. The remaining 3 studies defined ILM as recurrence
Table 1
Characteristics of included studies.
No. Author Year No.
patients
Age Follow-up (median) Breslow
(mm, mean)
Ulceration No. of
ILM
% ILM No. SLNB
patients
SN+ SN
Pts ILM Pts ILM
1 Bagley [12] 1981 103 NR >5 years (mean NR NR 5 4.9 NR N/A N/A N/A N/A
2 Janoff [14] 1982 122 NR 6.1 years (mean) NR NR 8 6.6 NR N/A N/A N/A N/A
3 Roses [13] 1983 658 NR 44.8 months (mean) NR NR 15 2.3 NR N/A N/A N/A N/A
4 Veronesi [59] 1991 612 0–20: 6
21–40: 217
41–50: 159
51–65: 230
90 months (mean) 1.0 NR 4 0.65 NR N/A N/A N/A N/A
5 Heenan [45] 1992 482 NR 5 years (mean) NR NR 7 0.62 NR N/A N/A N/A N/A
6 Gadd [60] 1992 1019 56 NR NR NR 89 8.7 NR N/A N/A N/A N/A
7 Fusi [44] 1993 1090 NR 84 months <0.75 6%
<2.25 38%
>2.25 56%
NR 20 1.8 NR N/A N/A N/A N/A
8 Martini [61] 1994 840 53.5 48 months 2.3 NR 24 2.9 NR N/A N/A N/A N/A
9 Karakousis [62] 1996 742 48.9 92 months (mean) 2.0 Present in 25%
NR 17
47 6.3 NR N/A N/A N/A N/A
10 Johnson [63] 1999 306 50.6 85 months (mean) NR NR 1 0.3 NR N/A N/A N/A N/A
11 Borgstein [16] 1999 258 NR 27 months 1.5 (median) NR 15 4.3 258 53 N/A 205 N/A
12 Cohn-Cedermark [46] 1999 2493 NR* 11 years 1.1–2.7
(median)**
NR* 49 1.97 NR N/A N/A N/A N/A
13 Cohn-Cedermark [64] 2000 989 51-52 (median) 11 years 1.2 (median) NR 9 0.9 NR N/A N/A N/A N/A
14 Chao [65] 2002 1183 52.0 16 months NR Present in 30%
NR 56
14 1.2 NR N/A N/A N/A N/A
15 Goydos [66] 2003 175 NR NR NR NR 14 8.0 175 102 14 73 0
16 Estourgie [35] 2003 250 NR 72 months 2.7 Present in 32%
NR 3
32 10.8 250 60 14 190 18
17 Borgognoni [67] 2004 375 55.3 35 months NR NR 7 1.9 375 75 1 300 6
18 Macripo [68] 2004 274 51 (median) 2.9 years 1.9 (median) Present in 8% 10 3.65 274 46 2 228 8
19 Thomas [69] 2004 900 57-58 60 months 3.1 (median) Present in 33%
NR 125
17 1.9 NR N/A N/A N/A N/A
20 Berk [70] 2005 260 55 29 months 2.3 Present in 25%
NR 33
3 1.15 260 39 1 221 2
21 Duprat [71] 2005 240 51 (median) 27.8 months 1.6 (median) Present in 30% 10 4.17 240 42 N/A 198 N/A
22 Nathansohn [72] 2005 141 53 41 months NR Present in 26%
NR 30
9 6.4 NR N/A N/A N/A N/A
23 Kang [20] 2005 4412 NR NR NR Present in 9%
NR 45.9%
77 1.7 1016 110 9 906 28
24 Van Poll [47] 2005 2018 57 44 months (mean) 2.4 Present in 26%
NR 258
54 2.7 754 102 7 652 11
25 Pawlik [10] 2005 1395 51 46.8 months 1.5 (median) Present in 21% 86 4.9 1395 234 28y 1136 40
26 Van Akkooi [73] 2006 262 NR 23.3 months 2.8 Present in 28% 11 4.2 262 77 7 185 4
27 Cecchi [74] 2006 111 53 (median) 31.5 months NR Present in 32%
NR 1
4 3.6 111 17 3 94 1
28 Kretschmer [75] 2006 328 60 (median) 40 months 2.7 Present in 34%
NR 16
25 7.6 NR N/A N/A N/A N/A
29 Dalal [76] 2007 1046 56 (median) 36 months (mean) 2.5 Present in 28%
NR 142
50 4.8 1046 163 23 883 27
30 Roulin [77] 2008 327 54 33 months 2.2 Present in 27% 20 6.1 327 74 10 253 10
31 UMCG database 2013 589 53 64.6 months 3.0 Present in 35%
NR 10
45 6.1 588 177 30 411 15
32 v/d Broek [78] 2013 305 51 >12 months 1.6 Present in 15%
NR 20
10 3.3 305 54 4 251 6
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S. Sloot et al. / Cancer Treatment Reviews 45 (2016) 120–128 123within the pathway of lymphatic drainage, between scar and regio-
nal nodal basin, and between tumor and nodes, respectively. Seven
out of 36 studies distinguished SL from ITM; out of these, 2 studies
defined SL and LR as the same entity [13,16,35,45–48].
ILM data review
ILM occurred most frequently in the WLE/DLND group (20/362
patients, 5.5%), followed by WLE/ELND (75/1682 patients, 4.5%),
WLE/SLNB (both SLNB+ and SLNB) (474/11,201 patients, 4.2%),
and WLE alone (285/14,729 patients, 1.9%). For the remaining
5648 patients, the occurrence of ILM was not specified according
to treatment method. This group includes Spillane et al. and Martin
et al, who did provide the amount of patients undergoing SLNB, but
did not differentiate recurrence rates for CLND/DLND/TLND and
CLND/TLND, respectively [49,50] (Table 2).
Of the 11,201 patients undergoing SLNB, ILM was split out
according to tumor status in 6913 patients. Of the SLNB+ group
153/1330 patients (11.5%) developed an ILM as FR versus
176/5783 patients (3.0%) in the SLNB group. Differences in distri-
bution between the four treatment modalities and differences
between SN and SN+ were statistically significant. ILM as FR after
WLE was significantly lower than after WLE/SLNB, WLE/ELND and
WLE/DLND (all p < 0.001). ILM was significantly lower after WLE/
SLNB compared to WLE/SLNB+ (p < 0.001) (Table 3).
Meta-analysis
After review of the data a meta-analysis was performed, with
weight assigned to studies based on the amount of included
patients. The overall ILM incidence was 3.4% (95% CI 2.8–4.2%). In
the meta-analysis, outcomes were similar to the review data with
ILM occurring most frequently in the WLE/DLND group (5.5%, 95%
CI 3.5–8.7%), followed by WLE/ELND (4.7%, 95% CI 3.1–7.0%), WLE/
SLNB (both SLNB+ and SLNB) (4.5%, 95% CI 3.5–5.7%) and WLE
alone (1.9%, 95% CI 1.4–2.7%) (Table 3 and Fig. 1). Of the 11,201
patients undergoing SLNB, ILM was split out according to tumor
status in 6913 patients. For the 6913 patients whose SLNB outcome
status was reported, ILM recurrence was higher than for the 11,201
patients, i.e. 5.8% (95% CI 4.1–8.3%). For SLNB+ patients, ILM occur-
rence was higher (13.2%, 95% CI 10.8–16.22%) than for SLNB
patients (3.4%, 95% CI 2.5–4.5%) (Fig. 2).
The WLE group had significantly less ILM recurrence than the
SLNB group (p = 0.02), but not than WLE/ELND and WLE/DLND
(p = 0.21 and p = 0.49, respectively). SLNB patients had less recur-
rence than SLNB+ patients (p = 0.01) (Table 3).Discussion
Background
In this review, 33,622 melanoma patients from 36 studies were
analyzed to establish whether performing SLNB on melanoma
patients in addition to WLE alone leads to an increase in ILM. This
is an ongoing field of discussion in the literature. In fact, Read et al.
recently published one of the largest databases so far, (n = 11,614)
where 505 patients developed ILM as a recurrence at any time dur-
ing follow-up [51]. ILM percentages were 4.7% and 21.6% for
SLNB and SLNB+ patients, respectively. Numbers were not speci-
fied for the 190 patients who developed ILM as FR, which explains
partly why the numbers are higher than in our study.
Critics of SLNB have argued that as of yet there is no agreement
on adjuvant therapy for node-positive patients and that only 20%
of the patients undergoing SLNB will have a positive node [52].
However, nowadays there are new approaches available with tar-
124 S. Sloot et al. / Cancer Treatment Reviews 45 (2016) 120–128geted and/or immunotherapies that may lead to new adjuvant
strategies [53,54]. The argument that no randomized controlled
studies have shown a survival advantage for SLNB in node-
positive patients has become partly redundant upon publication
of the MSLT-I, which shows a (small, but significant) survival
advantage for a selective group of patients, i.e. patients with an
intermediate thickness melanoma and positive SLNB. Proponents
advocate that SLNB is a procedure with a relatively low morbidity
and that the current false-negative rate for SLNB performed in rep-
utable institutes is <6%, declining further as experience progresses
[55,56].Table 2
Reviews classified by treatment, sorted by Breslow thickness for available studies.
Author Year No. patients
WLE (n = 7308)
Veronesi [59] 1991 612
Van Poll [47] 2005 1035
Martini [61] 1994 840
v/d Ploeg [80] 2014 2931
UMCG database [48] 2013 1
Cohn-Cedermark [64] 2000 989
Thomas [69] 2004 900
WLE + ELND (n = 609)
Karakousis [62] 1996 380
Van Poll [47] 2005 229
WLE + DLND (n = 362)
Karakousis [62] 1996 362
WLE + SLNB (n = 8868)
v/d Broek [78] 2012 305
Van Poll [47] 2005 754
Roulin [77] 2008 327
Berk [70] 2005 260
Dalal [76] 2007 1046
v/d Ploeg [80] 2014 2909
Estourgie [35] 2003 250
Van Akkooi [73] 2006 262
UMCG database 2013 588
Duprat [71] 2005 240
Pawlik [10] 2005 1395
Borgstein [16] 1999 258
Macripo [68] 2004 274
NR = not reported, classified as number of patients. ILM = intralymphatic metastases.
* Separate values given for separate treatment groups.
Table 3
Pooled values and total number of ILM in the treatment groups.
Treatmenta Pooled value from meta-analyses
Estimate
WLE 1.92
WLE + ELND 4.67
WLE + DLND 5.52
WLE + SLNB 4.46
SN 3.35
SN+ 13.24
Treatmentb Number of ILM
Total ILM (%)
WLE 14,729 285 (1.9)
WLE + ELND 1682 75 (4.5)
WLE + DLND 362 20 (5.5)
WLE + SLNB 11,201 474 (4.2)
SN 5783 176 (3.0)
SN+ 1330 153 (11.5)
a Pooled estimates from the meta-analyses, according to treatment as shown in Figs.
b Total number of ILM in the treatment groups for the initial treatments and stratifieResults
Based on the results of our meta-analysis, the overall incidence
of ILM as FR was 3.4%. Patients who did not undergo any lymph
node dissection had the lowest incidence, with 1.9% of patients
having ILM recurrence after WLE and 3.4% after SLNB. ILM occur-
rence after WLE/DLND and WLE/ELND was slightly higher (4.7%
and 5.5%, respectively), but incidence spiked after SLNB+/CLND at
13.2%. For TLND, insufficient data were available.
Differences in ILM occurrence between WLE and WLE/SLNB
groups were statistically significant, leading to the conclusion thatNo. of ILM Percentage ILM Breslow (mm)
4 0.65 1.0 mean
26 2.51 1.8 mean
24 2.85 2.3 mean
51 1.74 2.3* mean
0 0.00 3.0 mean
9 0.91 1.2 (median)
17 1.89 3.1 (median)
27 7.11 2.0 mean
10 4.37 3.2 mean
20 5.52 2.0 mean
6 2.0 1.6 mean
18 2.39 1.9 mean
20 6.12 2.2 mean
3 1.15 2.3 mean
50 4.78 2.5 mean
95 3.27 2.5* mean
27 10.80 2.7 mean
11 4.20 2.8 mean
45 7.65 3.0 mean
10 4.17 1.6 (median)
86 6.16 1.5 (median)
11 4.26 1.5 (median)
10 3.65 1.9 (median)
95% CI p-value
1.39–2.66 Reference value
3.10–7.04 0.21
3.50–8.70 0.49
3.51–5.67 0.02
2.52–4.46 Reference value
10.80–16.22 0.01
p-value
No ILM (%)
14,444 (98.1)
1607 (95.5)
342 (94.5)
10,727 (95.8) p-value four groups: <0.001
5607 (97.0)
1177 (88.5) SN and SN+: p < 0.001
1 and 2.
d for SN and SN+, review data. P-value for differences in distribution (Chi2).
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 86.6%, p = 0.000)
Kang
Cohn-Cedermark (1999)
Van Poll
Pawlik
Van Poll
WLE + ELND
Borgstein
Subtotal  (I-squared = 80.4%, p = 0.000)
Berk
Van Poll
Heenan
Roses
Thomas
Subtotal  (I-squared = 80.8%, p = 0.000)
Macripo
WLE + DLND
Martini
Karakousis
Cecchi
Subtotal  (I-squared = 61.1%, p = 0.036)
Roses
Van der Ploeg
Subtotal  (I-squared = .%, p = .)
ID
Roulin
WLE + SLNB
Kang
Dalal
Study
Van Akkooi
Karakousis
Ribero
Borgognoni
Ribero
Van der Ploeg
Janoff
Kang
Cohn-Cedermark (2000)
Johnson
Van den Broek
Estourgie
Goydos
Duprat
Veronesi
WLE
Sloot
3.40 (2.75, 4.20)
2.56 (1.32, 3.80)
1.97 (1.42, 2.53)
4.37 (1.72, 7.02)
6.16 (4.90, 7.42)
2.51 (1.56, 3.46)
4.26 (1.80, 6.72)
4.46 (3.51, 5.67)
1.15 (0.01, 2.45)
2.39 (1.30, 3.48)
1.45 (0.38, 2.52)
0.30 (0.01, 0.89)
1.89 (1.00, 2.78)
1.92 (1.39, 2.66)
3.65 (1.43, 5.87)
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Fig. 1. Pooled percentage of ILM according to treatment.
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in the risk of ILM (from 1.9% to 3.4%, p = 0.01).
To test the stasis hypothesis, the most comparable treatment
modalities regarding lymph flow disruption are WLE vs. WLE/
SLNB and WLE/SLNB+/CLND vs. WLE/ELND. As metastasis already
has occurred in WLE/DLND groups, this is not a good comparator.
As ILM incidence according to meta-analysis doubled between
WLE vs. WLE/SLNB and increased almost threefold from 4.7% to
13.2% between WLE/ELND and WLE/SLNB+/CLND groups,
(p < 0.001), the increase of ILM is unlikely to be due to the increase
in lymph stasis. CLND and ELND are comparable in their amount oflymph flow disruption. This suggests that an aggressive tumor
behavior is the main reason for ILM, a statement that is supported
by the spike in incidence after SLNB+, which is the patient group
with the most aggressive tumor biology.
Limitations
Inevitable to any review, authors use different definitions and
inclusion criteria. The level of heterogeneity is considerable, as
illustrated in Table 1, where data on patient and tumor character-
istics are shown. The inconsistent and varied application of terms
NOTE: Weights are from random effects analysis
.
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Fig. 2. Pooled percentage of ILM according to SLNB positive or negative result.
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some authors have even abandoned the concept of a true local
recurrence, merging ITM, SL and local recurrence into locoregional
metastasis, leading to considerable data loss [57]. Also, data on
mitosis index, Breslow thickness and ulceration status were incon-
sistent, thus complicating comparisons, necessitating interpreting
the results with caution. In general, patients included in SLNB stud-
ies have less favorable primary tumor characteristics than patients
who undergo WLE alone [58]. Moreover, before introduction of the
SLNB technique, patients with less favorable tumor characteristics
were to undergo ELND and would therefore not be included inWLE
studies. These limitations may account for the difference between
this review and the MSLT-I, a prospective study, in which no
increase in ILM or local metastasis was reported between biopsy
and observation groups (7.7 ± 1.0% and 8.4 ± 1.3%, respectively;
p = 0.38). As we included WLE patients before introduction of SLNB
our WLE population would differ from the MSLT-I population.
The percentage of ILM after DLND in our study is lower than
expected. This may be due to the small sample size and also due
to bias as we only included ILM as FR after DLND. Since these
patients have aggressive disease, they may more often progress
to distant metastasis instead of locoregional disease.
Summary
This review showed an increase in ILM of 1.5% after only per-
forming a SLNB procedure (ILM 1.9% for WLE vs. 3.4% for SLNB).Taking into account the patient groups traditionally included in
WLE studies it is difficult to say whether this increase represents
an actual increase in ILM recurrence or a selection bias.
The SLNB procedure is the most important prognostic tool in
clinical practice, providing a survival benefit in selected SLNB+
patients undergoing CLND and potentially serving as a marker to
identify patients for adjuvant therapy. Sentinel lymph node biopsy
has been suspected of causing to increase intralymphatic metasta-
sis by restricting lymph flow. This review demonstrates this
increase, but this result has to be interpreted with caution due to
possible selection bias. As the stasis hypothesis seems to be incor-
rect based on the data in this study, aggressive tumor characteris-
tics are likely the cause of this increase. We therefore advocate
performing SLNB procedures, but to proceed with caution, adhere
to the guidelines and not extend the indication area.Conflict of interest statement
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